Achieve Life Sciences Inc (FRA:SP4P)
€ 4.575 -0.105 (-2.24%) Market Cap: 159.89 Mil Enterprise Value: 114.71 Mil PE Ratio: 0 PB Ratio: 3.51 GF Score: 35/100

Achieve Life Sciences Inc at LD Micro Invitational Conference Transcript

Jun 07, 2023 / 03:30PM GMT
Release Date Price: €5.8 (-2.52%)
Unidentified_Participant

Good morning, everyone. I hope you all had a great evening last night or well rested. I'm excited to introduce to you our first presentation of the day, from Achieve Life Sciences, please welcome to the stage, John Bencich.

John Bencich
Achieve Life Sciences, Inc. - CEO

Morning, everyone. Before we get going, just want to remind everyone I may be making forward-looking statements as part of this presentation, so I encourage everyone to take a look at our filings on SEC.gov and the risk factors contained therein.

At Achieve Life Science, we're focused on the development and ultimately, commercialization of a drug called cytisinicline as an aid to smoking cessation and treatment for nicotine addiction. This is a bit of a unique molecule. This is a product that's been on the market in Europe for 20 years plus, over which time it has treated over 20 million patients.

But it's also a product that's never been brought to the US or any major markets, and that was the opportunity that we identified several years back. Which was to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot